Bicara Therapeutics BCAX 深 沪
等待开盘 10-31 09:30:00 美东时间
16.46
+0.580
+3.65%
华盛通- 最 高16.81
- 今 开15.76
- 成交量 45.73万股
- 最 低 15.42
- 昨 收 15.88
- 总市值 8.98亿
- 52周最高 24.585
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 7.80
- 委 比 34.76%
- 总股本 5456.28万
- 历史最高 28.09
- 量 比 0.69
- 振 幅 8.75%
- 历史最低 7.80
- 每 手 1
- 风险率 3.74%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Nanomedicine Breakthrough Technology Redefining Drug Delivery, Bioavailability in Oncology
NetworkNewsWire Editorial Coverage NEW YORK, Oct. 27, 2025 /PRNewswire/ -- The global oncology market is rapidly shifting toward smarter drug-delivery systems that enhance efficacy, reduce t...
10-27 20:30
Bicara Therapeutics Announces Ficerafusp Alfa Granted Breakthrough Therapy Designation by U.S. FDA for 1L HPV-Negative R/M HNSCC
The FDA has granted Breakthrough Therapy Designation (BTD) to ficerafusp alfa in combination with pembrolizumab for the first-line treatment of patients with metastatic or unresectable, recurrent (R/M) head and neck squamous cell carcinoma (HNSCC) whose tumors express PD-L1 with a combined positive score (CPS) ≥1, excluding HPV-positive oropharyngeal cancer. This designation recognizes the urgent need for effective therapies in HPV-negative HNSCC...
10-13 11:30
4 Biotech Stocks Seeing Explosive Momentum Gains
The SPDR S&P Biotech ETF (ARCA:XBI) is up more than 40% over the past six months and is on the verge of breaking out. Here's a look at several momentum standouts in the biotech space that appear to be rapidly gaining strength.
10-07 23:19
Bicara Therapeutics Files For Mixed Shelf Offering Of Up To $400M
https://www.sec.gov/Archives/edgar/data/2023658/000119312525230307/d54249ds3.htm
10-04 04:35
Genmab reportedly nearing deal to acquire cancer drugmaker Merus
Danish biotech Genmab (GMAB) is in advanced discussions to acquire Merus (NASDAQ:MRUS), a Dutch drug developer targeting head and neck cancer, Bloomberg News reported on Sunday, citing people familiar...
09-29 07:58
Bicara Therapeutics to Participate in Upcoming Investor Conferences
Boston, Aug. 27, 2025 – Bicara Therapeutics Inc. announced that its management will participate in three upcoming investor conferences in September 2025. The meetings include the Cantor Global Healthcare Conference, the Wells Fargo Healthcare Conference, and the Morgan Stanley Global Healthcare Conference. Live webcasts and replays will be available on the company's Investor Relations website. Bicara is focused on developing bifunctional therapi...
08-27 20:01
Piper Sandler initiates coverage of oncology companies
Piper Sandler launched coverage for a few biotech companies in the oncology space, as mentioned below: CG Oncology (NASDAQ:CGON) rated Overweight with a $55 price target: "Investor expectations for cr...
08-19 23:17
Piper Sandler Initiates Coverage On Bicara Therapeutics with Overweight Rating, Announces Price Target of $36
Piper Sandler analyst Kelsey Goodwin initiates coverage on Bicara Therapeutics (NASDAQ:BCAX) with a Overweight rating and announces Price Target of $36.
08-19 19:48
Bicara Therapeutics Q2 EPS $(0.50) Beats $(0.54) Estimate
Bicara Therapeutics (NASDAQ:BCAX) reported quarterly losses of $(0.50) per share which beat the analyst consensus estimate of $(0.54) by 7.41 percent. This is a 97.37 percent increase over losses of $(19.01) per share
08-12 19:33
Bicara Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
Bicara Therapeutics reported financial results and updates on its lead drug, ficerafusp alfa, for Q2 2025. The company has $437 million in cash, expected to fund operations into 2029. Updated Phase 1/1b data showed strong responses in HPV-negative recurrent/metastatic HNSCC patients, with a 54% objective response rate and 46% 2-year OS rate. Additional Phase 1b expansion cohorts are ongoing, with data expected in Q1 2026. R&D expenses rose due to...
08-12 11:30
